#Demis Hassabis

Demis Hassabis's Isomorphic Labs: $2.7B Raised, Trials Due This Year

Isomorphic Labs raised $2.7B total through May 2026. How the pharma deals with Lilly and Novartis work, what IsoDDE changed, and when trials begin.

Architectural Interactivity, Linguistic Interpretability, and Molecular Synthesis: The Frontier of Native AI

Three organisations now define the frontier of native AI: Thinking Machines is rebuilding human-AI collaboration as a low-latency interaction model, the Effable movement wants interpretable safety frameworks like SafetyAnalyst, and Isomorphic Labs is converting AlphaFold into an end-to-end drug design engine. The common thread is moving from AI as a layer of abstraction toward AI as a fundamental component of human and biological systems.

Demis Hassabis in 2026: How DeepMind Is Turning AlphaFold Into a Drug Discovery Engine

Demis Hassabis has spent 2026 arguing that AlphaFold is the first rung in an AI-powered scientific revolution. Here is how his thesis maps to Isomorphic Labs' drug pipeline, DeepMind's research agenda, and his view that the generative AI boom may paradoxically slow deeper progress.

Demis Hassabis on AI's Future: Beyond Current Models

Demis Hassabis, CEO of Google DeepMind, discusses the current limitations of AI, the path to AGI, and the future of AI in scientific discovery.

Hassabis: The AI Shift Is 100x Faster Than the Industrial Revolution

DeepMind's Veo and the "Learnable Nature" of Reality

AGI's Coming in 5 to 10 years, says DeepMind CEO Demis Hassabis

He says there's "50% chance" of achieving what he defines as AGI within the "next 5 to 10 years." He clarifies that AGI implies a system exhibiting "all the cognitive capabilities we have as humans," not LLMs.